Premium
Embryonic Stem Cells: From Bench to Bedside
Author(s) -
Pucéat M,
Ballis A
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100298
Subject(s) - embryonic stem cell , bench to bedside , regenerative medicine , stem cell , induced pluripotent stem cell , medicine , clinical trial , somatic cell , neuroscience , intensive care medicine , biology , pathology , microbiology and biotechnology , medical physics , genetics , gene
As early as their derivation, embryonic stem (ES) cells have attracted a great attention to clinicians. Derived from early embryos, these cells remain pluripotent in culture while they can be expanded in principle without limit. They give rise to most progenies and differentiate to all major somatic lineages of potential use in regenerative medicine. The great therapeutic promises put forward almost 10 years ago to cure or relieve degenerative diseases are still up to date. However, cell therapy is a complex process that significantly differs from drug‐based medicine. Although a clinical trial has been announced by GERON for next year to cure spinal cord injury, many issues remain to be addressed at the bench before these cells can be used in clinics. Clinical Pharmacology & Therapeutics (2007) 82 , 337–339; doi: 10.1038/sj.clpt.6100298 ; published online 18 July 2007